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Introduction: The aim of this study was to assess the use of 201thallium3+ (201Tl3+) as a radiolabel for nuclear imaging tracers. Methods for
labeling of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″ tetraacetic acid (DOTA) and diethylenetriaminepentaacetic acid (DTPA) chelators
with 201Tl3+ were investigated, and the levels of stability of these chelates were tested in vitro and in vivo.
Methods: 201Tl(I)Cl was treated with hydrochloric acid and ozone to form 201Tl(III)Cl3. The procedure for labeling of DOTA and DTPA was
optimized, testing different buffer solutions and pH values. The stability levels of 201Tl(III)–DOTA and 201Tl(III)–DTPA were assessed in
buffer, mouse serum and human serum (1:1, v/v) at a temperature of 310 K for 48 h. Subsequently, in vivo stability studies with 201Tl(III)–
DOTA were performed, comparing the biodistribution of 201Tl(III)–DOTA with that of 201Tl(I)Cl in a single-isotope study and with that of
177Lu(III)–DOTA in a dual-isotope single photon emission computed tomography study.
Results: 201Tl(III)–DTPA, 201Tl(III)–DOTA and 177Lu(III)–DOTA were prepared with N95% radiochemical purity. While 201Tl(III)–
DOTA showed a prolonged level of stability in buffer and serum, 201Tl was quickly released from DTPA in serum. Apart from some urinary
excretion, the biodistribution of DOTA-chelated 201Tl3+ was similar to that of free (ionic) 201Tl+ and did not match the biodistribution of
177Lu(III)–DOTA. This indicated a limited stability of 201Tl(III)–DOTA complexes in vivo.
Conclusion: Despite promising results on the labeling and in vitro stability of 201Tl(III)–DOTA, our in vivo results indicate that the integrity
of 201Tl(III)–DOTA decreases to b20% during the time required for urinary excretion, thereby limiting the use of 201Tl3+ as a radiolabel for
tracer imaging.
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Single photon emission computed tomography (SPECT)
is a widely used nuclear imaging modality with main
application in bone scans and cardiac perfusion imaging.
Most radiopharmaceuticals for SPECT are labeled with
radionuclides such as technetium-99m (99mTc), indium-111
(111In) and iodine-123 (123I) [1]. These radionuclides are
preferred due to their well-suited γ-emission characteristics⁎ Corresponding author. Biomedical NMR, Department of Biomedical
Engineering, Eindhoven University of Technology, 5600 MB Eindhoven,
The Netherlands. Tel.: +31 0 612932309.
E-mail address: h.gruell@tue.nl (H. Grüll).
0969-8051/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.nucmedbio.2010.10.009with photon energies in the range of 50–250 keV and due to
their straightforward labeling chemistry based on binding to
suitable chelates (99mTc, 111In) or covalent attachment (123I).
In clinical SPECT, the radionuclide thallium-201 (201Tl) is
also used routinely to assess myocardial stress [2], as well as
for imaging tumor development [3,4]. In these procedures,
201Tl is injected as ionic 201Tl+, after which it is taken up by
the cells via potassium channels.
The radiophysical properties of 201Tl, a half-life of 3.04
days and γ-emissions at 72 keV (X-ray, 94% abundance),
135 keV (3% abundance) and 167 keV (10% abundance),
make it an excellent radionuclide for SPECT imaging. These
properties, together with the wide availability and low cost of
this radionuclide, make it worthwhile to investigate the use
of Tl for direct labeling of radiopharmaceuticals. So far,
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diethylenetriaminepentaacetic acid (DTPA) and 1,4,7,10-
tetraazacyclododecane-N,N′,N″,N′″ tetraacetic acid (DOTA)
is a little explored field. Labeling of EDTA with (cold) Tl
was described in the late 1970s [5,6]. The labeling of
dithiocarbamate with 201Tl was previously investigated for
applications in neuroimaging [7]. Chavatte et al. [8] were the
first to investigate radiolabeling of DTPA with 201Tl. In these
studies, Tl3+ chelates were found to be stable in buffer
solution: log K1=48.0 for Tl(III)–DTPA and log K1=38.9 for
Tl(III)–EDTA, K1=[ML]/[M][L] at 293.15 K [5]. Recently,
Jalilian et al. [9] showed successful labeling of DTPA and
vancomycin with 201Tl. No publications on 201Tl–DOTA
chelates were found.
In general, DOTA forms more stable chelates than DTPA
because of its macrocyclic structure, which “cages” the metal
ion [10]. Considering that the cavity of the DOTA chelate
fits best ions with a radius of about 1 Å, ionic Tl3+, with a
radius of 1.03 Å, was expected to be well suited for the
labeling of DOTA and its derivatives. The Tl ion in the
oxidation state I (Tl+) has a larger size (1.64 Å), leading to
chelates that are generally less stable compared with Tl3+
chelates [6]: log K1=5.97 for Tl(I)–DTPA and log K1=6.53
for Tl(I)–EDTA, K1=[ML]/[M][L] at 293.15 K [5].
The stability of Tl3+ chelates is thus impaired by possible
reduction from Tl3+ to Tl+. Under standard conditions
(neutral pH and room temperature), the most stable oxidation
state of nonchelated thallium is I; however, both Tl+ and Tl3+
can exist under biological conditions [11].
TlþXTl3+ + 2e− E- = + 1:25V ð1Þ
O2 + H2O X O3 + 2H
þ + 2e− E- = + 2:07V ð2Þ
The standard redox potential of E°=+1.25 V of the
Tl+/Tl3+ redox couple indicates that strong oxidizing
conditions are needed to oxidize Tl+ to Tl3+ (Eq. (1)) [12].
It further implies that oxidized Tl3+ will be easily reduced to
Tl+ in an acidic environment, unless the higher oxidation
state is electrostatically stabilized by the coordination of the
Tl3+ ion to a negatively charged chelate, which could
significantly reduce the redox potential of the resulting
Tl(III) complex. Under physiological conditions, a reduction
to Tl+ may nevertheless occur, upon which fast dechelation is
expected due to the generally lower stability constant of the
resulting Tl(I) complex. It is therefore important to increase
the relative stability of the Tl(III) complex under physiolog-
ical conditions as much as possible by choosing a negatively
charged chelator with a large binding strength. DOTA is
particularly suitable in this respect, because it combines a
high coordinating strength based on the macrocyclic effect
with the high negative charge of a potentially tetraanionic
chelator [13].
A method for the oxidation of 201Tl(I)Cl to 201Tl(III)Cl3
using ozone was previously reported [8]. The oxidation
strength of ozone is strongly dependent on the pH of theenvironment, with a redox potential of E°=+2.07 V at pH 0
(Eq. (2)) [12]. At pHN0, the redox potential decreases
according to Eq. (3) [13].
E = EB − 0:029V log
O3½  Hþ½ 2
O2½  H2O½  ð3Þ
Therefore, during the oxidation process, an acidic
environment is required to ensure a sufficiently high
oxidation strength of the ozone; however, after labeling, a
neutral or basic pH is required to deprotonate the chelator
and stabilize the 201Tl(III) complex that has been formed in
the presence of the respective chelate.
In this study, use of 201Tl3+ as a radiolabel for SPECT
imaging is assessed. A method for Tl(III)–DOTA labeling is
presented and compared with Tl(III)–DTPA labeling. The
levels of stability of these chelates have been studied in
buffer, mouse serum and human serum. Subsequently, the
stability of 201Tl(III)–DOTA in mice is investigated by
comparing its biodistribution with that of 177Lu(III)–DOTA,
which is known to be stable in vivo [14], in single- and dual-
isotope SPECT and γ-counting studies.2. Materials and methods
2.1. Synthesis of cold Tl(III)–DOTA
Commercially available nonradioactive Tl(III)Cl3 tetra-
hydrate (Sigma-Aldrich, USA) was used for initial synthesis
of Tl(III)–DOTA. Tl(III)Cl3 (0.59 mmol) was added to a
suspension of H4DOTA (0.59 mmol, Macrocyclics, USA) in
methanol (7 ml). Four equivalents of sodium methoxide
(NaOCH3, 2.34 mmol) were added for deprotonation of
H4DOTA, and the mixture was heated under reflux for 30
min, whereupon a white precipitate was formed. The product
was isolated by filtration, washed with methanol (1 ml) and
acetone (three times, 1 ml) and dried over silica to yield
white crystals (35 mg), which were analyzed with Fourier
transform infrared (FT-IR) spectroscopy and electrospray-
ionization mass spectrometry (ESI-MS). Cyclovoltammetry
measurements were performed to determine the potential of
the Tl(I)–DOTA/Tl(III)–DOTA redox couple.
2.2. Oxidation of 201Tl
Commercially available 201Tl(I)Cl (thallous chloride
solution, 85 MBq in 2.3 ml at calibration time, Mallinckrodt,
The Netherlands) was mixed with 2 M HCl [30:1, 300 μl of
201Tl(I)Cl, 10 μl of HCl, pHfinalb2.0]. Ozone was produced
from medical-grade oxygen using an ozone generator (Enaly
1000BT-12, China) and was bubbled through the mixture for
20 min (flow rate≈10 ml/min) to produce Tl3+ according to:
Tlþ + O3 + 2HþYTl3+ + O2 + H2O ð4Þ
For radiation safety, a nonradioactive vial was used to check
the flow rate prior to switching to the 201Tl-containing vial.
587N.M. Hijnen et al. / Nuclear Medicine and Biology 38 (2011) 585–592Filters were placed on the gas outlets to prevent 201Tl
contamination of the environment. Contact with metal-
containing materials was prevented. Oxidation of Tl+ to Tl3+
was checked with normal-phase silica instant thin-layer
chromatography (ITLC, Pall Corporation, USA) using
acetone as the mobile phase. 201Tl3+ (Rf=1.0) separated
from 201Tl+ (Rf=0.0). ITLC strips were analyzed using a
phosphor imager (FLA-7000, Fujifilm, Japan).
2.3. Labeling of DOTA with 201Tl3+
H4DOTA was dissolved in different metal-free buffer
solutions to optimize labeling conditions. Ammonium acetate
buffer (0.25 M) at pH 5.5, pH 6.5, pH 7.5, pH 8.0 and pH 9.0
and sodium citrate buffer (0.25 M) at pH 5.5 were assessed
(1 mg of H4DOTA per milliliter of buffer, 2.0 mM). Thirty
microliters of oxidized 201Tl(III)Cl3 was added to 300 μl of
DOTA solution in a glass reaction vial [15]. The vial was
subsequently flushed with ozone. The reaction was per-
formed at a temperature of 291 K for 90 min while shaking.
Different mobile phases were assessed for checking the
labeling efficiency with TLC. The use of acetonitrile in
Millipore-purified water (30%, v/v) as the mobile phase on
reversed-phase silica TLC (60 RP-18F254s, Merck, Germany)
gave the best separation between 201Tl(III)–DOTA (Rf=1.0),
201Tl3+ (Rf=0.1) and
201Tl+ (Rf=0.0). The labeling efficiency
was checked with TLC at different time intervals (0, 30, 60
and 90 min). In the case of N5% free 201Tl presence, the
compound was purified using solid-phase extraction with
NH2 Sep-Pak cartridges (Waters, USA). The cartridges were
conditioned with 96% ethanol (5 ml) and equilibrated with
0.9% NaCl (5 ml). The crude labeling mixture was loaded on
the Sep-Pak cartridge, and the product was eluted in fractions
containing 5% ethanol (100 μl per fraction). After purifica-
tion, the radiochemical purity was again assessed using
reversed-phase silica TLC and the pH was adjusted to 7.4 for
in vivo injection.
2.4. Labeling of DTPA with 201Tl3+
H5DTPA was dissolved in 0.25 M ammonium acetate
buffer at pH 8.0 (1 mg H5DTPA/ml, 2.5 mM). Thirty
microliters of oxidized 201Tl(III)Cl3 was added to 300 μl of
DTPA in solution. The vial was flushed with ozone. The
reaction was performed at 291 K for 60 min while shaking.
Reversed-phase silica TLC using acetonitrile in Millipore-
purified water as the mobile phase was performed to assess
the radiochemical purity. 201Tl(III)–DTPA (Rf=1.0) sepa-
rated from free 201Tl3+ (Rf=0.1) and
201Tl+ (Rf=0.0).
2.5. Labeling of DOTA with 177Lu3+
H4DOTA was dissolved in 0.05 M ammonium acetate
buffer at pH 5.5 (1 mg H4DOTA/ml, 2.0 mM). A total of
1.5 μl of 177Lu(III)Cl3 (67 MBq) was added to 50 μl of
DOTA solution. The crude mixture was placed in a heating
block at 353 K for 45 min while shaking. The labeling
efficiency was checked with reversed-phase silica TLC usingacetonitrile in Millipore-purified water as the mobile phase
(30%, v/v) [177Lu(III)–DOTA Rf=1.0,
177Lu3+ Rf=0.1]. The
mixture was diluted with Millipore-purified water (125 μl),
and the pH was adjusted to 7.4 for in vivo injection.
2.6. In vitro stability levels of 201Tl(III)–DOTA and 201Tl(III)–
DTPA complexes
The levels of stability of the 201Tl(III)–DOTA and 201Tl
(III)–DTPA chelates were investigated in ammonium acetate
buffer (pH 9.0 and pH 8.0, respectively), mouse serum and
human serum. Two hundred microliters of the chelates was
mixed with 200 μl of buffer or serum (1:1, v/v) and placed
shaking at 310 K for 48 h. A control sample was flushed with
nitrogen before incubation in mouse serum in order to ensure
that traces of ozone did not influence the results. The
radiochemical purity was analyzed at different time intervals
with reversed-phase silica TLC using acetonitrile in Milli-
pore-purified water (30%, v/v) as the mobile phase.
2.7. SPECT imaging and biodistribution studies of
201Tl(I)Cl, 201Tl(III)–DOTA and 177Lu(III)–DOTA
The in vivo distributions of 201Tl(I)Cl, 201Tl(III)–DOTA
and 177Lu(III)–DOTA were investigated in normal BALB/c
nu/nu mice (age, 11–15 weeks). All animal experiments
were approved by the animal welfare committee of the
Maastricht University Hospital (The Netherlands) and were
performed according to the U.S. National Institutes of Health
principles of laboratory animal care [16] and the Dutch
national law “Wet op de Dierproeven” (Std 1985, 336). Two
mice received a 201Tl(I)Cl injection into the tail vein (≈20
MBq in 100 μl). One mouse was sacrificed at 5 min
postinjection and the other mouse at 1 h postinjection to have
a direct comparison between imaging and biodistribution
data at these two time points. Combined SPECT/CT scans
were acquired postmortem using a dedicated small-animal
SPECT/CT system equipped with four detector heads and
converging multi-pinhole collimators (nine pinholes per
collimator, 0.8-mm resolution, nanoSPECT/CT, Bioscan,
USA). Five mice were injected with 201Tl(III)–DOTA into
the tail vein (≈10 MBq in 100 μl), five mice were injected
with 177Lu(III)–DOTA into the tail vein (≈40 MBq in
100 μl) and five other mice were injected with a mixture of
201Tl(III)–DOTA (≈10 MBq) and 177Lu(III)–DOTA (≈40
MBq) in 100 μl into the tail vein. A four-time excess of 177Lu
activity was used as compared with 201Tl activity to
compensate for the lower natural abundance of the measured
γ-emissions of 177Lu. All radiopharmaceuticals had a
radiochemical purity N95% at the time of injection. The
mice were continuously scanned under anesthesia, which
was induced and maintained by isoflurane inhalation (1%–
3%) in medical air (flow, 0.4–0.6 l/min) during the first 4 h
postinjection (dynamic scan time was 45 min). After 4 h, the
animals were sacrificed and scanned postmortem.
The five mice that were injected with a mixture of
201Tl(III)–DOTA and 177Lu(III)–DOTAwere scanned using
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ic scan time, 45 min; energy windows, 30% around 72
keV and 20% around 113, 167 and 208 keV). Simultaneous
201Tl/177Lu acquisition was optimized (Supplemental Fig.
1), and the acquired signal was corrected for cross-
contamination occurring due to spectral overlap of the two
radionuclide signals and Compton scattering using cross-
contamination removal software (InVivoScope version 1.41,
Bioscan). Postmortem scans (scan time, 192 min) were
acquired for good counting statistics, immediately followed
by γ-counting. After reconstruction, volumes of interest
were selected using both SPECT and CT postmortem
acquired data. All regions were drawn in threefold and
averaged to minimize drawing variation. The sum activity in
the regions of interest was converted to Becquerel using a
predetermined quantification factor and expressed as a
percentage of the injected dose per volume (% ID/cm3).
All animals were dissected after scanning. The radioac-
tivity levels in urine, blood, heart, lung, liver, spleen, left
kidney, muscle and thigh bone were determined using γ-
counting (Wizard 1480, Perkin Elmer, The Netherlands).
Radioactive uptake in these tissues was calculated as the
percentage of the injected dose per gram of tissue (% ID/g).ig. 1. Stability levels of 201Tl(III)–DOTA (A) and 201Tl(III)–DTPA (B)
omplexes in buffer, mouse serum and human serum. The kinetics of 201Tl
lease from the DOTA chelate can be described using a single exponential
t (dashed lines).3. Results
3.1. Synthesis of Tl(III)–DOTA
The nonradioactive Tl(III)–DOTA complex was synthe-
sized, isolated and subsequently analyzed using ESI-MS and
FT-IR. The amount of free DOTA present after synthesis was
b5%, based on ESI-MS results (Supplemental Fig. 2). The
measured molecular weight of the chelate as detected by ESI-
MS in the negative ion mode was 605 g/mol, which is in
accordance with the calculated value for the Tl(III)–DOTA
anion Tl(III)–DOTA−. After synthesis, the characteristic IR
bands of free H4DOTA were absent in the FT-IR spectrum of
the isolated Tl(III) complex (Supplemental Fig. 3). The
sharpening of the peaks in the IR spectrum of the solid NaTl
(III)–DOTA compared with that of free H4DOTA indicated
metal binding. FT-IR measurements were performed before
and after purification of the compound. The fingerprint region
of the spectra remained unchanged. Cyclovoltammetry
measurements showed that the redox potential of the Tl(I)–
DOTA/Tl(III)–DOTA couple [E≈+0.1 V vs. normal hydro-
gen electrode (NHE)] was lower than the potential of Tl+/Tl3+
(E≈+0.9 V vs. NHE), indicating stabilization of the oxidation
state III of Tl by the complex (Supplemental Fig. 4).
3.2. Labeling of DOTA and DTPA with 201Tl3+
Oxidation of commercially available 201Tl(I)Cl to
201Tl(III)Cl3 was successful using the ozone oxidation
method described above (yield, N98%). ITLC measurements
showed that the oxidation state III remained stable in the
acidic oxidizing environment for at least 3 days.DOTA labeling with 201Tl3+ was assessed in several
buffer solutions. The highest radiochemical purity was
obtained when using ammonium acetate buffer at pH 9.0
(N95% after 60 min), which could be further improved by
purification with NH2 Sep-Pak cartridges.
201Tl(III)–DOTA
showed a slightly lower retention on NH2 cartridges
compared with 201Tl. 201Tl(III)–DOTA eluted in the second
and third 100-μl fractions of 5% ethanol, followed by 201Tl
eluting in subsequent fractions containing 5%, 7.5% or 10%
ethanol. Labeling of DTPA with 201Tl3+ was more efficient
than labeling of DOTA with 201Tl3+. Within 30 min, N90%
of the present 201Tl was chelated by DTPA as compared with
70% chelated 201Tl(III)–DOTA using the same protocol.
3.3. In vitro stability levels of 201Tl(III)–DOTA and 201Tl
(III)–DTPA complexes
The levels of stability of 201Tl(III)–DOTA (Fig. 1A) and
201Tl(III)–DTPA (Fig. 1B) chelates over time were assessed
in buffer, mouse serum and human serum. Labeling of
DTPA with 201Tl3+ was more efficient than labeling of
DOTA with 201Tl3+. Both chelates were stable in ammoniumF
c
re
fi
ig. 2. Combined SPECT/CT images showing the biodistributions of 201Tl 5
in (A) and 1 h (B) postinjection of 201Tl(I)Cl (≈20 MBq) via the tail vein
can time, 192 min; inhalation anesthesia, 1%–3% isoflurane in medical air
low, 0.4–0.6 l/min)].
ig. 3. Biodistribution results of 201Tl 5 min postinjection of ≈20 MBq
1TlCl (n=1) (A) and 1 h postinjection via the tail vein (n=1) (B) from both
PECT (% ID/cm3) and γ-counting (% ID/g).
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DTPA chelate was less stable in serum than the 201Tl(III)–
DOTA chelate (“easy in=easy out”). Flushing with nitrogen
to remove potential traces of ozone did not influence the
stability of the 201Tl(III)–DOTA chelate in serum. 201Tl(III)–
DOTA remained stable in mouse and human sera long
enough for in vivo SPECT imaging studies [radiochem-
ical purity N80% up to 4 h, compared with 15% radio-
chemical purity after 4 h in serum for 201Tl(III)–DTPA]
to be performed.
3.4. SPECT imaging and biodistributions of 201Tl(I)Cl,
201Tl(III)–DOTA and 177Lu(III)–DOTA
The in vivo stability of the 201Tl(III)–DOTA complex
was investigated by comparing its biodistribution with that
of ionic 201Tl+ in a single-isotope study and with that of
177Lu(III)–DOTA in a dual-isotope study. The latter
compound is known to be stable in vivo with rapid excretion
via the kidney and subsequent accumulation in the urine
[17]. As reference, the biodistribution of 177Lu(III)–DOTA
was measured separately in a single-isotope study. Dynamic
imaging showed that 177Lu(III)–DOTA was excreted via the
urine, resulting in a strong increase of activity in the bladder
over time and a decrease in the kidneys (total uptake in 4 h,
from 4% to 1% ID/cm3) (Figs. 4B, 5B and 6). Minor uptake
was found in other tissues (b2% ID/cm3), indicating
complex stability [17].
As second reference, the biodistribution of ionic 201Tl+
was measured. 201Tl+ ions behave in the body as a potassium
mimic [18]. In humans, free Tl+ accumulates in the viable
myocardium within 10 min, after which it rapidly clears from
the blood. Blood clearance occurs primarily through uptake
in myocardium, kidneys, liver, thyroid and stomach, with the
remaining 201Tl+ distributing uniformly throughout the body
[18]. In the study described here, a similar behavior of 201Tl+
ions was expected, but with much faster uptake and
clearance due to the higher metabolic rate of mice as
compared with humans.
The biodistribution of 201Tl in a mouse observed after 5
min is shown in Fig. 2A. Main uptake was found in the
kidneys and heart, with some 201Tl distributed over the
limbs' muscles. After 1 h, 201Tl washout from the heart was
almost complete. At this time point, the main uptake was
observed in the kidneys, while no 201Tl excretion was
observed in the urine (Fig. 2B). Quantification of the 201Tl
uptake per organ as determined by SPECT and γ-counting is
shown in Fig. 3, showing comparable results between
SPECT and γ-counting.
The biodistribution of 201Tl(III)–DOTA was imaged over
time during the first 4 h after injection in a single-isotope
study. Main 201Tl uptake was found in the kidneys (Figs. 4A
and 5A), which increased slightly over time (average
increase in 4 h, 4% ID/cm3) (Fig. 6). Apart from activity
in the kidneys, urinary excretion was observed. Minor
(around 5% ID/cm3) uptake was found in all other tissues, asF
m
[s
(fcomparable with the results after injection of ionic 201Tl+.
Since no urinary excretion was observed after the injection of
ionic 201Tl+, urinary excretion after injection of 201Tl(III)–
DOTA was considered indicative of the presence of some
intact 201Tl(III)–DOTA during the first 45 min postinjection.
For further evaluation of the in vivo complex stability
(including urinary excretion) of 201Tl(III)–DOTA, the
biodistribution of 201Tl(III)–DOTA was directly compared
with that of 177Lu(III)–DOTA in a dual-isotope study.
Therefore, 201Tl(III)–DOTA was injected simultaneously
with 177Lu(III)–DOTA into the same mouse. The biodis-
tribution of both complexes was imaged simultaneously with
dual-isotope SPECT followed by a postmortem scan with
long acquisition time (Fig. 4C) and γ-counting (Fig. 5C).
The dual-isotope study showed no 177Lu activity in any of
the organs besides the kidneys, as was the case for 201TlF
20
S
Fig. 4. Combined SPECT/CT images showing the biodistributions of single-
isotope 201Tl(III)–DOTA (≈10MBq) (A) and 177Lu(III)–DOTA (≈40MBq)
(B) and dual-isotope 177Lu(III)–DOTA (≈40 MBq, yellow–green color
map) and 201Tl(III)–DOTA (≈10 MBq, blue–purple–white color map) (C),
all 4 h postinjection via the tail vein [scan time, 192 min; inhalation
anesthesia, 1%–3% isoflurane in medical air (flow, 0.4–0.6 l/min)].
ig. 5. Biodistribution results of single-isotope 201Tl(III)–DOTA (≈10
Bq) (n=5) (A), single-isotope 177Lu(III)–DOTA (≈40 MBq) (n=4) (B)
nd dual-isotope 177Lu(III)–DOTA (≈40 MBq) and 201Tl(III)–DOTA (≈10
Bq) (n=4) (C) from both SPECT (% ID/cm3) and γ-counting (% ID/g), all
h postinjection via the tail vein.
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correspondence with the distribution found postinjection of
201Tl(I)Cl; however, the kidney retention of 201Tl was
lower in mice that received a 201Tl(III)–DOTA injection
(17.4%±5.7% ID/g) than for the mice that were injected with
201Tl(I)Cl (48.8%±3.8% ID/g). The absolute biodistribution
values quantified for each isotope were similar to the
biodistribution values found in the separate single-isotope
studies (Fig. 7).
The urinary excretion of 201Tl (13.4%±1.5% ID) in the
dual-isotope study was far lower than the urinary excretion
of 177Lu (81.3%±4.0% ID), as measured simultaneously in
the same mice. Assuming 100% stability of the 177Lu(III)–
DOTA complex, no urinary excretion of free 201Tl and
complete homology in the biodistribution of the 201Tl(III)–
DOTA and 177Lu(III)–DOTA complexes, this would
indicate that only 16.5% of the 201Tl remained chelated by
DOTA during the time required for urinary excretion.4. Discussion
Prior work showed that Tl3+ forms stable complexes with
chelators such as DTPA, EDTA and dithiocarbamate. Here,
for the first time, a (cold) Tl(III)–DOTA complex wasF
M
a
M
4synthesized, isolated and characterized. The complex
remained stable at room temperature under air. Electrochem-
ical characterization of the complex indicated a lower redox
potential of the Tl(I)–DOTA/Tl(III)–DOTA couple com-
pared with the Tl+/Tl3+ redox couple that possibly could lead
to a higher level of stability of the Tl(III) complex in
biological media. Radiolabeled 201Tl(III)–DOTA was pre-
pared, characterized and compared with 201Tl(III)–DTPA
and 177Lu(III)–DOTA in order to assess the stability of
201Tl(III)–DOTA in vivo. Radiolabeling with 201Tl3+
required first the oxidation of commercially available
201Tl(I)Cl to 201Tl(III)Cl3. Here, an ozone oxidation
method was used, which had the advantage over other
oxidation methods of not requiring an extra purification
step after the oxidation. The obtained 201Tl3+ was chelated
by DOTA or DTPA within 30 min with a radiochemical
purity of N95% after purification using NH2 Sep-Pak
cartridges. The presence of ozone improved the labeling
yield significantly, which was expected from the redox
properties of the Tl+/Tl3+ couple.
Fig. 6. 201Tl activity (A) and 177Lu activity (B) in the left kidney over time
postinjection of 201Tl(III)–DOTA (≈10 MBq) (n=5) and 177Lu(III)–DOTA
(≈40 MBq) (n=4), respectively.
ig. 7. 201Tl activity and 177Lu activity in the left kidney (A) and bladder (B)
ver time after simultaneous injection of 201Tl(III)–DOTA (≈10 MBq) and
7Lu(III)–DOTA (≈40 MBq) (n=5).
591N.M. Hijnen et al. / Nuclear Medicine and Biology 38 (2011) 585–592The 201Tl(III)–DOTA chelate was stable in ammonium
acetate buffer at 310 K. In mouse and human sera, the
radiochemical purity gradually decreased to 70% after 48 h
(N80% up to 4 h). The 201Tl(III)–DOTA complex showed
superior stability compared with the corresponding DTPA
complex. The latter was stable in ammonium acetate buffer
at 310 K, but the radiochemical purity quickly decreased in
human and mice sera. Only 15% of the 201Tl remained
chelated by DTPA in serum after 4 h.
The in vivo stability of the 201Tl(III)–DOTA complex
was assessed using both single- and dual-isotope SPECT
studies, comparing the biodistribution of ionic 201Tl+ with
those of 201Tl(III)–DOTA and 177Lu(III)–DOTA.
Our results suggest that 201Tl is significantly released
from the DOTA chelate in vivo in mice, probably due to a
reduction of the Tl(III)–DOTA complex to Tl(I)–DOTA
followed by rapid dechelation. While ionic 201Tl+ showed no
excretion into the urine, a stable Tl(III) complex was
expected to show a biodistribution comparable with that of
177Lu(III)–DOTA with almost complete excretion into the
urine. In our studies with 201Tl(III)–DOTA, some urinary
excretion of 201Tl was found, combined with a lower kidneyF
o
17retention as compared with 1 h postinjection of ionic 201Tl+.
In a direct comparison of 177Lu(III)–DOTA and 201Tl(III)–
DOTA using dual-isotope SPECT imaging, no 177Lu activity
was observed in specimens other than kidney tissue and
urine, while 201Tl activity was recovered in all specimens
(see Figs. 4C and 5C). The latter was also observed in
biodistribution studies using ionic 201Tl+. The dual-isotope
study allowed determination of the ratio between both
isotopes in all organs and urine, as any potential urine loss
would affect both isotopes equally. Based on the dual-
isotope data, we estimate that less than 20% of the 201Tl(III)–
DOTA remained stable long enough for urinary excretion.5. Conclusion
In this contribution, the chemistry, radiochemistry and in
vitro and in vivo stabilities of 201Tl(III)–DOTA complexes
have been investigated and compared with those of known
592 N.M. Hijnen et al. / Nuclear Medicine and Biology 38 (2011) 585–592201Tl(III)–DTPA complexes. While 201Tl(III)–DOTA
showed prolonged stability in buffer and serum, the
201Tl(III)–DTPA complex quickly decomposed in serum.
The use of 201Tl(III)–DTPA for in vivo applications was
therefore not considered. In a dual-isotope SPECT study,
201Tl(III)–DOTA chelates showed a rapid release of 201Tl in
vivo. Although 201Tl has very suitable radiophysical
properties for SPECT imaging, it cannot be used as a
radiolabel in tracer imaging research using DOTA-conju-
gated targeting moieties. This study shows that dual-isotope
SPECT is a valuable tool in assessing and comparing the
biodistributions of new tracers labeled with different radio-
nuclides in the same animal.
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